302 related articles for article (PubMed ID: 12743496)
1. [Diagnosis of the follicular variant of papillary thyroid carcinoma. Significance of immunohistochemistry].
Guyétant S; Michalak S; Valo I; Saint-André JP
Ann Pathol; 2003 Feb; 23(1):11-20. PubMed ID: 12743496
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical diagnosis of papillary thyroid carcinoma.
Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of CD15, galectin-3 and HBME-1 expression in follicular thyroid neoplasms].
Bogdańska M; Górnicka B; Ziarkiewicz-Wróblewska B; Koperski L; Morton M; Wasiutyński A
Endokrynol Pol; 2006; 57(4):314-9. PubMed ID: 17006830
[TBL] [Abstract][Full Text] [Related]
4. [The use of immunohistochemistry in the differential diagnosis of thyroid gland tumors with follicular growth pattern].
Laco J; Ryska A
Cesk Patol; 2006 Jul; 42(3):120-4. PubMed ID: 16955558
[TBL] [Abstract][Full Text] [Related]
5. Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma.
Vasko VV; Gaudart J; Allasia C; Savchenko V; Di Cristofaro J; Saji M; Ringel MD; De Micco C
Eur J Endocrinol; 2004 Dec; 151(6):779-86. PubMed ID: 15588246
[TBL] [Abstract][Full Text] [Related]
6. High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors.
Raphael SJ; McKeown-Eyssen G; Asa SL
Mod Pathol; 1994 Apr; 7(3):295-300. PubMed ID: 7520169
[TBL] [Abstract][Full Text] [Related]
7. Interpretation of RET immunostaining in follicular lesions of the thyroid.
Cerilli LA; Mills SE; Rumpel CA; Dudley TH; Moskaluk CA
Am J Clin Pathol; 2002 Aug; 118(2):186-93. PubMed ID: 12162676
[TBL] [Abstract][Full Text] [Related]
8. Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors.
Paunovic I; Isic T; Havelka M; Tatic S; Cvejic D; Savin S
APMIS; 2012 May; 120(5):368-79. PubMed ID: 22515291
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma.
Nakamura N; Erickson LA; Jin L; Kajita S; Zhang H; Qian X; Rumilla K; Lloyd RV
Endocr Pathol; 2006; 17(3):213-23. PubMed ID: 17308358
[TBL] [Abstract][Full Text] [Related]
10. Follicular, papillary, and "hybrid" carcinomas of the thyroid.
Castro P; Fonseca E; Magalhães J; Sobrinho-Simões M
Endocr Pathol; 2002; 13(4):313-20. PubMed ID: 12665649
[TBL] [Abstract][Full Text] [Related]
11. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
Park KY; Koh JM; Kim YI; Park HJ; Gong G; Hong SJ; Ahn IM
Clin Endocrinol (Oxf); 1998 Sep; 49(3):317-23. PubMed ID: 9861322
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas.
Saggiorato E; Aversa S; Deandreis D; Arecco F; Mussa A; Puligheddu B; Cappia S; Conticello S; Papotti M; Orlandi F
J Endocrinol Invest; 2004 Apr; 27(4):311-7. PubMed ID: 15233548
[TBL] [Abstract][Full Text] [Related]
13. Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hürthle cell and/or apocrine-like changes.
Mai KT; Bokhary R; Yazdi HM; Thomas J; Commons AS
Histopathology; 2002 Feb; 40(2):133-42. PubMed ID: 11952857
[TBL] [Abstract][Full Text] [Related]
14. [Cytokeratin expression of benign and malignant epithelial thyroid gland tumors. An immunohistologic study of 154 neoplasms using 8 different monoclonal cytokeratin antibodies].
Schröder S; Wodzynski A; Padberg B
Pathologe; 1996 Nov; 17(6):425-32. PubMed ID: 9082363
[TBL] [Abstract][Full Text] [Related]
15. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
[TBL] [Abstract][Full Text] [Related]
16. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.
Tallini G; Santoro M; Helie M; Carlomagno F; Salvatore G; Chiappetta G; Carcangiu ML; Fusco A
Clin Cancer Res; 1998 Feb; 4(2):287-94. PubMed ID: 9516913
[TBL] [Abstract][Full Text] [Related]
17. Follicular adenoma with papillary architecture: a lesion mimicking papillary thyroid carcinoma.
Mai KT; Landry DC; Thomas J; Burns BF; Commons AS; Yazdi HM; Odell PF
Histopathology; 2001 Jul; 39(1):25-32. PubMed ID: 11454041
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
Rossi ED; Raffaelli M; Mule' A; Miraglia A; Lombardi CP; Vecchio FM; Fadda G
Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
[TBL] [Abstract][Full Text] [Related]
19. [Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis].
He CN; He L; Cheng JQ; Chen SC; Zhao HF; Zhai JP; Zhang J
Zhonghua Bing Li Xue Za Zhi; 2008 Jan; 37(1):35-9. PubMed ID: 18509983
[TBL] [Abstract][Full Text] [Related]
20. Papillary carcinoma of the thyroid: a tumour still with no benign neoplastic counterpart.
Stephenson TJ
Histopathology; 2001 Nov; 39(5):536-8. PubMed ID: 11737313
[No Abstract] [Full Text] [Related]
[Next] [New Search]
